Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation (Q46072562)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

title

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

author name string

Z Wang

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

F Xuan

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

W H Lin

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

M D Troyer

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

A Tendolkar

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

D L Cutler

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

publication date

16 July 2013

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

published in

European Journal of Clinical Pharmacology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

volume

69

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

issue

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

page(s)

1761-1767

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

cites work

Adverse events from the treatment of Parkinson's disease.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00228-013-1541-5

retrieved

21 January 2018

Adenosine A2A receptors and Parkinson's disease.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00228-013-1541-5

retrieved

21 January 2018

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00228-013-1541-5

retrieved

21 January 2018

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00228-013-1541-5

retrieved

21 January 2018

Effects of cisapride on QT interval in children.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00228-013-1541-5

retrieved

21 January 2018

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS00228-013-1541-5

retrieved

21 January 2018

Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23857248

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23857248

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00228-013-1541-5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

PubMed publication ID

23857248

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23857248

retrieved

19 December 2017

reference URL

http://europepmc.org/abstract/MED/23857248

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46072562&oldid=2207604950"